Investor directory

Air Street Capital

Air Street Capital is a London-based venture capital firm established in 2018 that focuses on investing in early-stage companies within the artificial intelligence and life sciences sectors. The firm is comprised of a diverse team of experienced investors, engineering leaders, entrepreneurs, and AI researchers who have backgrounds in leading technology companies and research institutions. Air Street Capital seeks to partner with entrepreneurs developing AI-first technology solutions that address significant challenges in various industries. The firm emphasizes investments in intelligent systems that can solve previously unaddressed problems and improve upon the performance of existing technologies. With a strong commitment to fostering innovation, Air Street Capital aims to create enduring companies that have a meaningful impact on their respective markets, particularly in sectors such as finance technology, software-as-a-service, and health technology across the United States, Canada, and Europe.
https://www.airstreet.com
https://angel.co/company/air-street-capital-1
https://crunchbase.com/organization/air-street-capital
https://linkedin.com/company/airstreetcapital
https://pitchbook.com/profiles/investor/266064-22
https://signal.nfx.com/firms/air-street-capital
https://twitter.com/airstreet

Nathan Benaich Ph.D

Founder & General Partner

15 past transactions

Anagenex

Series A in 2022
Developer of drug discovery platform designed for radically accelerating small molecule drug discovery and finding pharmaceutical compounds for medically important targets. The company's technology rapidly analyzes compounds by combining machine learning with DNA-encoded libraries to generate enormous amounts of useful data and parallel biochemical experiments using proprietary artificial intelligence (AI) models, enabling researchers to develop new drugs.

Gandeeva Therapeutics

Series A in 2022
Gandeeva Therapeutics has developed a proprietary platform that combines innovative technologies across biochemistry, structural biology, imaging and machine learning to characterize protein-drug interactions at the atomic level, all designed to provide new insights into targeting protein function.

Anagenex

Seed Round in 2022
Developer of drug discovery platform designed for radically accelerating small molecule drug discovery and finding pharmaceutical compounds for medically important targets. The company's technology rapidly analyzes compounds by combining machine learning with DNA-encoded libraries to generate enormous amounts of useful data and parallel biochemical experiments using proprietary artificial intelligence (AI) models, enabling researchers to develop new drugs.

InVivo AI

Seed Round in 2021
InVivo AI is a Montreal-based company founded in 2017 that specializes in using artificial intelligence to enhance pharmaceutical research and development. The company primarily focuses on preclinical toxicology, aiming to improve the efficiency and effectiveness of drug development processes. By leveraging advanced AI technologies, InVivo AI seeks to transform traditional methodologies in the pharmaceutical industry, ultimately contributing to faster and more reliable outcomes in drug safety assessments.

intenseye

Series A in 2021
Intenseye Inc. operates a video analytics platform. The product can be used to track variety of objects and extract information from videos and cameras in a secure way. The product provides real-time camera feeds for applications in occupational health and safety, retail consumer analytics, and outdoor advertising. Intenseye Inc. was founded in 2018 and is based in San Jose, California.

Modern Intelligence

Venture Round in 2021
Modern Intelligence is a technology company using proprietary advances in information and complexity theory to build one AI for defense. The company's hierarchical approach provides a dramatic scaling advantage over classical neural networks, naturally enabling very high accuracy on few-shot learning for novel problems, and in many cases, the ability to solve previously-unsolvable problems. Modern Intelligence was founded in 2020 and is based in San Jose, CA.

GOURMEY

Seed Round in 2021
GOURMEY is a pioneering cultivated meat company based in Paris, France, founded in 2019. It specializes in developing and producing ethical foie gras derived from duck cells, aiming to transform the traditional meat industry. GOURMEY's mission focuses on facilitating a humane and sustainable transition in meat production by harvesting meat directly from animal cells. By reinventing France's renowned delicacy, GOURMEY seeks to promote a healthier and more ethical approach to meat consumption.

intenseye

Seed Round in 2021
Intenseye Inc. operates a video analytics platform. The product can be used to track variety of objects and extract information from videos and cameras in a secure way. The product provides real-time camera feeds for applications in occupational health and safety, retail consumer analytics, and outdoor advertising. Intenseye Inc. was founded in 2018 and is based in San Jose, California.

V7

Seed Round in 2020
V7 Ltd develops toolkit for computer vision AI. It develops image and video datasets for collaborative projects. Its solutions offer filter, tag, and sync data via the API and its interface. The company was incorporated in 2018 and is based in London, United Kingdom.

Allcyte

Seed Round in 2020
Allcyte is a biotech start-up company focused on functional drug testing in primary human material. With our Pharmacoscopy high-content imaging platform and AI-supported image analysis pipelines, our mission is to bring the next generation of personalized medicine to cancer patients and treating physicians, and support pharmaceutical companies to focus their drug development efforts on the right molecules in the right indications. We enable research through the image-based quantification of single-cell phenotypes - all performed directly in primary patient material with minimal amounts of manipulation and requiring minimal amounts of sample. We integrate these data using cutting edge methods of statistics and machine learning to generate actionable insights for our customers. Our mission is to help you make the best possible biomedical decisions.

LabGenius

Series A in 2019
LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed EVA, a robotic scientist that autonomously designs, conducts, and learns from experiments. LabGenius utilizes a machine learning-driven evolution engine within its protein engineering platform, combining advanced technologies from machine learning, synthetic biology, and robotics to develop innovative protein therapeutics.

Mission Barns

Seed Round in 2019
Mission Barns, Inc., founded in 2018 and based in Berkeley, California, specializes in producing cell-cultured meat from animal cells. The company cultivates animal cells in a nutrient-rich environment, allowing for the sustainable growth of meat while minimizing the negative impacts associated with traditional animal farming. By leveraging advancements in biotechnology and food science, Mission Barns aims to provide juicy and savory meat products in a more efficient and environmentally friendly manner. The company's approach is designed to contribute to a more sensible food system, addressing the growing demand for sustainable food solutions.

Vtrus

Seed Round in 2019
Vtrus develops ABI (Autonomy Brain Implant): A modular unit that enables robots to understand the world around them. The system abstracts away perception, planning and control, presenting a simpler message-passing interface to developers to quickly get robotics projects off the ground. Welcome the era of Software-Defined Robotics.

Mission Barns

Seed Round in 2018
Mission Barns, Inc., founded in 2018 and based in Berkeley, California, specializes in producing cell-cultured meat from animal cells. The company cultivates animal cells in a nutrient-rich environment, allowing for the sustainable growth of meat while minimizing the negative impacts associated with traditional animal farming. By leveraging advancements in biotechnology and food science, Mission Barns aims to provide juicy and savory meat products in a more efficient and environmentally friendly manner. The company's approach is designed to contribute to a more sensible food system, addressing the growing demand for sustainable food solutions.